Abstract:Enlightened by our previous efforts to modify diarylpyrimidines as HIV-1 non-nucleoside reverse transcriptase (RT) inhibitors (NNRTIs) and the reported crystallographic studies, we designed and synthesized novel 1,2,3-triazole-derived diarylpyrimidine derivatives via the CuAAC "click reaction", to make additional interactions with the hydrophobic channel in the NNRTI binding pocket. The newly synthesized compounds were evaluated for anti-HIV potency in MT-4 cells. All the compounds showed favorable activity against the wild-type HIV-1 strain with an EC50 of 0.013-5.62 μM. Interestingly, some compounds displayed remarkable potency in inhibiting K103N mutant virus, a key drug-resistant mutant to NNRTIs. Among them, meta-methylbenzoate (ZL2, EC50(IIIB) = 0.020 μM, EC50(K103N) = 0.043 μM, CC50 > 241.52 μM), para-methylbenzoate (ZL3, EC50(IIIB) = 0.013 μM, EC50 (K103N) = 0.022 μM, CC50 > 241.52 μM) and para-phenol (ZL7, EC50(IIIB) = 0.014 μM, EC50 (K103N) = 0.054 μM, CC50 = 2.1 μM) derivatives are the three most promising compounds which are superior to the first-line antiretroviral drug efavirenz (EC50(IIIB) = 0.003 μM, EC50 (K103N) = 0.11 μM, CC50 > 6.34 μM) against the K103N mutant strain. More encouragingly, ZL2 and ZL3 exhibited much lower cytotoxicity and a high selection index of >10 000 compared with all the control drugs (AZT, 3TC, NVP, EFV, and ETV). The detailed structure-activity relationship (SAR), enzymatic inhibitory activity and docking study of the representative compounds are also discussed. Furthermore, the preliminary physicochemical properties and the early metabolic stability of representative compounds were examined to evaluate their drug-like properties.

Discovery of Novel Fused-heterocycle-bearing Diarypyrimidine Derivatives As HIV-1 Potent NNRTIs Targeting Tolerant Region I for Enhanced Antiviral Activity and Resistance Profile

Identification of novel diarylpyrimidine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against wild-type and K103N mutant viruses

Discovery of novel diarypyrimidine derivatives bearing six-membered non-aromatic heterocycles as potent HIV-1 NNRTIs with improved anti-resistance and drug-like profiles

Structure-based design of diarylpyrimidines and triarylpyrimidines as potent HIV-1 NNRTIs with improved metabolic stability and drug resistance profiles

Design, Synthesis and Anti-Hiv Evaluation of Novel Diarylpyridine Derivatives Targeting the Entrance Channel of NNRTI Binding Pocket.

Discovery of Novel Diarylpyrimidine Derivatives As Potent HIV-1 NNRTIs Targeting the "NNRTI Adjacent" Binding Site

Discovery of diarylpyrimidine derivatives bearing piperazine sulfonyl as potent HIV-1 nonnucleoside reverse transcriptase inhibitors

Boronic Acid-Containing Diarylpyrimidine Derivatives As Novel HIV-1 NNRTIs: Design, Synthesis and Biological Evaluation

Structure-based design and optimization lead to the identification of novel dihydrothiopyrano[3,2- d]pyrimidine derivatives as potent HIV-1 inhibitors against drug-resistant variants

Targeting the Hydrophobic Channel of NNIBP: Discovery of Novel 1,2,3-Triazole-derived Diarylpyrimidines As Novel HIV-1 NNRTIs with High Potency Against Wild-Type and K103N Mutant Virus

Discovery of Novel Amino Acids (Analogues)-Substituted Thiophene[3,2- d]pyrimidine Derivatives as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Design, Synthesis, and Biological Evaluation

Discovery of Diarylpyridine Derivatives As Novel Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.

Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp3 values and favorable drug-like properties

Exploring the Hydrophobic Channel of NNIBP Leads to the Discovery of Novel Piperidine-Substituted Thiophene[3,2-D]pyrimidine Derivatives As Potent HIV-1 NNRTIs

Identification of Dihydrofuro[3,4- D]pyrimidine Derivatives As Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.

Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs

Discovery of 2,4,6-Trisubstituted Pyrimidine Derivatives As Novel Potent Hiv-1 Nnrtis by Exploiting the Tolerant Region Ii of the Nnibp

Development of Novel Dihydrofuro[3,4- d ]pyrimidine Derivatives as HIV-1 NNRTIs to Overcome the Highly Resistant Mutant Strains F227L/V106A and K103N/Y181C

Discovery of Novel Pyridazinylthioacetamides As Potent Hiv-1 Nnrtis Using A Structure-Based Bioisosterism Approach

Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives As Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency Against Resistance-Associated Variants

Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives As HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.